PSMA expression levels, which are associated with androgen signaling, can significantly influence the efficacy of PSMA-targeted therapies, positioning PSMA as a promising target for innovative prostate cancer treatments [33]. This evidence concerns the gene FOLH1 and prostate carcinoma.